Blood Test and Immunotherapy for Bladder Cancer
Trial Summary
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on any immunosuppressive agents or systemic corticosteroids above a certain dose within 14 days before joining the trial. It's best to discuss your specific medications with the trial team.
Research shows that drugs targeting the PD-1/PD-L1 pathway, like Nivolumab and similar treatments, have been effective in treating advanced bladder cancer. These drugs help the immune system attack cancer cells, and several have been approved for use in bladder cancer, indicating their potential effectiveness.
12345This treatment is unique because it uses immunotherapy drugs like Durvalumab and Avelumab, which are antibodies that target PD-L1, a protein that helps cancer cells hide from the immune system. Unlike traditional chemotherapy, these drugs enhance the body's immune response to fight cancer, offering a different approach with potentially fewer side effects.
12678Eligibility Criteria
This trial is for adults with bladder cancer who've had their bladders and lymph nodes surgically removed recently. It's not for those who only had part of the bladder taken out or have heart failure, severe hearing loss, bad peripheral neuropathy, or poor overall health. Participants should not have any remaining visible cancer after surgery.Inclusion Criteria